The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-When will a vaccine be ready? Here's a guess!

Wed, 13th May 2020 11:58

* European shares slump on virus fears

* Banks hit by earnings

* EZ industry output suffers record fall in March
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

WHEN WILL A VACCINE BE READY? HERE'S A GUESS! (1050 GMT)

Assuming that countries in Europe aren't aiming at the so called "herd immunity", which
involves 60 to 90% of the population being infected by coronavirus, a vaccine could be the key
to return to a pre COVID-19 life.

A limited number of vaccine doses could be available before year end, says the European
pharma team at Credit Suisse.

With unlimited potential demand and governments controlling the vaccine distribution, supply
could jump to more than 1 billion doses by mid-2021.

The Swiss bank expects first safety data from human trials in the next few months from
Oxford/Astrazeneca, Sinovac and Novavax.

Once the vaccine is out there, for every 100 million doses CS sees a potential uplift to
2025 EPS of 2.6% for Sanofi, 2.3% for Astrazeneca and 1.1% GlaxoSmithKline.

The pharma team modelled sales/profits based on the current $5-6 billion flu vaccine market
where the average price per dose is $10 and over 200 million doses are produced annually.

(Stefano Rebaudo)

*****

CAUTIOUS AND SELECTIVE STOCKS RECOVERY LOOMING (0845 GMT)

The most likely scenario now is a cautious recovery in stock markets, as fears of a second
wave of infections will weigh at least for a while but huge stimulus programs already under way
will prop up share prices.

The latest rally was all about P/E ratio expansion after the ECB "opened the liquidity tap"
and the "markets internals are not risk-on" yet, Barclays says in a research note.

In this scenario the investment bank suggests "to use dips to add selectively to cyclicals,"
after downgrading Telecoms to underweight, while it is overweight on Tech, Mining, Cap Goods,
Healthcare and Utilities in defensives.

Barring the feared second wave of the virus, the economy will show signs of recovery and we
should not forget that "buying equities when PMIs bottom has been a typically better strategy
than buying when they are peaking."

If PMIs rebound and "history repeats itself, cyclicals should outperform".

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: RISK-OFF MOOD HITS BANKS, VODAFONE UP (0737 GMT)

Risk-off mood gripped the financial markets on fresh fears about a second wave of the
coronavirus outbreak, while the gradual easing in lockdowns is under way.

Banks, and automotive sectors are the worst hit, down almost 3%. While utilities, retail and
telcos are standing their ground even if in negative territory.

ABN Amro is among the top losers in the Stoxx 600 index, down 7.1%, after a 395 million euro
loss, hit by loan provisions of 1.1 billion euros. Commerzbank shares down more than 3% after
posting a loss in Q1.

Arcelormittal under further pressure, after some target price cuts by investment banks. The
company recently announced an issue of shares and convertible notes worth $2 billion.

Agnelli's family holding company Exor is down 4.7% after French insurer Covea walked away
from its planned $9 billion purchase of the Bermuda-based reinsurer PartnerRe.

Vodafone shares in positive territory, as the company posted on Tuesday results in
line with expectations and said it would maintain its dividend.

(Stefano Rebaudo)

*****

NEGATIVE RATES, THE ULTIMATE FED 'PUT'? (0713 GMT)

There's nothing like the smell of negative interest in the morning to spice things up!

Powell's speech this afternoon (1300 GMT) will definitely be a key moment for the session
after Trump pressured the Fed to look into "the gift" of negative rates.

"I am looking at that bounce back in US e-minis, and once again, investors are counting on
Fed Chair Powell to grease the wheels off yet another equity markets recovery rally", writes
AxiCorp strategist Stephen Innes, pointing out to positive Wall Street futures currently
outperforming European bourses in the red.

"All that policy deluge before even thinking about negative rates, which is arguably their
ace in the hole for more rainy days, has got investors lining up for their rally bus tickets
again", he commented.

This could of course very well also end up in a case of 'buy the rumour, sell the news' if
Powell brushes off the idea of going subzero.

"The central banker might use the opportunity to nip the negative rates chatter in the bud",
warned at CMC Markets analyst David Madden.

Anyhow, we still got a few hours to wait so let's take a look at the last 20 years of the 10
year U.S. benchmark and see if we can see a trend about where it's heading:

(Julien Ponthus)

*****

ON THE RADAR: L'OREAL, BANKS, ASTON MARTIN AND VOLVO (0635 GMT)

European bourses are coming under renewed selling pressure as fears of a new wave of
infections are gripping financial markets.

On the corporate front, L'Oreal decided to give up on share buyback programmes in
2020 and on a planned 10.4% dividend increase, but to stick to the same 2019 payout per share of
3.80 euros.

More banks are swinging to the red in the first quarter. Commerzbank posted a worse than
expected net loss of 295 million euros, as the lender undergoes a restructuring due to the
coronavirus outbreak. Commerzbank shares are down 2.3% in early trade.

Ducth bank ABN Amro reported a 395 million euro loss, hit by loan provisions of 1.1 billion
euros. Meantime, Deutsche Bank top managers will waive one month of fixed pay, in an effort to
cut costs; shares are down 2% in early trade.

The travel and leisure industry stays on the radar as TUI said it needed to cut
its fixed cost base by 30% and thousands of jobs as it looks to right-size its business to
survive.

Car makers Aston Martin posted a first-quarter pretax loss of 119 million pound,
after sales dropped by nearly a third, while Volvo ditched dividend payment.

Moller-Maersk first-quarter revenue were in line with expectations, but the company warned
about a drop of as much as 25% in global container volumes in the second quarter.

Alstom is sticking to the terms of its previously agreed deal to buy the rail
division of Canada's Bombardier for up to 6.2 billion euros.

But another acquisition falls through with Exor saying it will retain control of
Bermuda-based reinsurer ParnerRe after Covea walked away from the $9 billion deal acquisition.

Eiffage first-quarter construction revenue slumped 13.0%.

Salvatore Ferragamo, whose core profits plunged by 82.2% to 12 million euros in the three
months to March said it could not provide guidance on expected sales for 2020.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE RED ON RENEWED CORONAVIRUS FEARS (0636)

European futures are in the red amid fears of a fresh spike in coronavirus cases and renewed
U.S.-China tensions.

Wall Street's fall overnight seems set to hit a fragile European market, which has recently
swung between optimism over some easing in lockdowns and anxiety about a second wave of
infections.

U.S. markets sentiment soured after U.S. infectious disease expert Anthony Fauci warned that
a premature lifting of social distancing measures could lead to additional outbreaks.

Fresh trade war fears also emerged when a leading U.S. Republican senator proposed
legislation that would authorize Trump to impose sanctions on China if it fails to give a full
account of events leading to the outbreak.

(Stefano Rebaudo)

*****

(Reporting by Joice Alves, Julien Ponthus and Stefano Rebaudo)

More News
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.